Amiodarone Administration Guidelines

Introduction to Amiodarone Administration

The American Academy of Pediatrics recommends that in pulseless VT/VF (cardiac arrest), Amiodarone 5 mg/kg (maximum 300 mg) can be given as a rapid bolus, and may be repeated up to a total daily dose of 15 mg/kg 1
The American Heart Association suggests that this rapid administration is appropriate only after defibrillation and epinephrine have been initiated 1
In life-threatening situations, the American College of Cardiology recommends that the 300 mg dose can be administered over 15 minutes and repeated after one hour if needed 4

The American Heart Association recommends standard dosing of 150 mg IV over 10 minutes, which may be repeated if necessary, for hemodynamically stable patients 2, 3
The American College of Cardiology suggests that this is followed by maintenance infusion: 1 mg/min for 6 hours, then 0.5 mg/min 2, 3
The European Society of Cardiology notes that the antiarrhythmic effect may take up to 20-30 minutes to manifest 4, 5

The American Family Physician reports that hypotension occurs in 16% of patients receiving IV amiodarone and is directly related to infusion rate 6
The American College of Cardiology states that bradycardia and heart block occur in 4.9% of patients with IV administration 6
The American Heart Association recommends that if hypotension or bradycardia develops, the infusion should be discontinued or the rate reduced 6

The American Academy of Pediatrics recommends that for pediatric VT/supraventricular tachycardia with pulse, 5 mg/kg (maximum 300 mg) over 20-60 minutes, with administration rate adjusted to urgency 1
The American College of Cardiology suggests that for stable wide-complex tachycardia or atrial fibrillation, 5-7 mg/kg over 30-60 minutes is recommended 7
The European Society of Cardiology notes that rapid administration in stable patients risks unnecessary hypotension 7, 8

The American Heart Association states that absolute contraindications to rapid IV administration include severe sinus node dysfunction, marked sinus bradycardia, second- or third-degree AV block without pacemaker 1, 6
The American College of Cardiology recommends that amiodarone should not be used with other QT-prolonging drugs without expert consultation 1
The American Academy of Pediatrics suggests that it requires continuous ECG monitoring and immediate defibrillator availability 1

The American Family Physician warns that rapid bolus should not be given in stable patients, as the delayed onset of action means rapid administration provides no therapeutic advantage in non-arrest situations while significantly increasing hypotension risk 4, 5
The American College of Cardiology recommends that central line is preferred, as peripheral administration causes phlebitis; use central venous access when possible 6
The American Heart Association suggests that concentration matters, and continuous infusion should not exceed 2 mg/mL concentration and must be diluted in D5W 1
The American Academy of Pediatrics notes that because of its 14-58 day terminal half-life, cardiologist consultation is recommended when considering amiodarone outside cardiac arrest settings 1